Weekly News Recap #Phispers | PharmaCompass.com

Trump signs ‘most favored nation’ executive order to slash drug costs; Sanofi, Takeda pledge mega investments in US

The US President Donald Trump’s dramatic intervention in pharmaceutical pricing took centerstage as the White House unvei...

Impressions : 597

BMS to invest US$ 40 bn to boost US manufacturing, R&D; 19 states sue Trump admin for gutting health agencies

US President Donald Trump’s tariff threats appear to be working, as Bristol Myers Squibb became the latest drugmaker to a...

Impressions : 1477

AbbVie, Amgen, Thermo Fisher to invest in US manufacturing to avoid tariffs; Merck KGaA acquires SpringWorks for US$ 3.9 bn

Ever since US President Donald Trump has talked about a “major tariff” on drug imports coming “very shortly&r...

Impressions : 717

Roche announces US$ 50 bn investment in US to avoid tariffs; Regeneron signs US$ 3 bn onshoring deal with Fujifilm

After Eli Lilly, Johnson & Johnson and Novartis, Roche has announced plans to manufacture in the US to avoid tariffs. The Swiss...

Impressions : 933

Novartis to invest US$ 23 bn in US to avoid import tariffs; Pfizer halts development of GLP-1 weight-loss pill

After Eli Lilly and Johnson & Johnson, Novartis has become the latest big pharma to announce mega investments in the US. The ...

Impressions : 884

Pharma tariffs coming soon, warns Trump; GSK, Lilly ink billion-dollar deals for blood-brain barrier technology

In this week’s news, US President Donald Trump has said “major” pharmaceutical import tariffs are coming soon...

Impressions : 1048

CBER director forced out in FDA gutting; Sanofi, Alnylam’s RNAi therapy Qfitlia wins US approval for hemophilia A, B

The pharma industry saw its most tumultuous week in the recent past with the US Food and Drug Administration (FDA) facing an un...

Impressions : 944

J&J plans US$ 55 bn investment in US to avoid Trump’s tariffs; Astra to invest US$ 2.5 bn in Chinese R&D centre

This week’s Phispers brings you lots of news from China. AstraZeneca is investing US$ 2.5 billion in a new Beijing resear...

Impressions : 833

Mallinckrodt, Endo merge in US$ 6.7 bn deal; Astra buys cell therapy developer EsoBiotec; Pfizer sells entire stake in Haleon

In Phispers this week, two drugmakers emerging from bankruptcy — Mallinckrodt and Endo — are merging in order to le...

Impressions : 1127

Roche buys rights to Zealand’s obesity med in US$ 5.3 bn deal; Merck wins Gardasil lawsuit, bolsters vaccine manufacturing

In news this week, Roche has acquired rights to develop and commercialize Zealand Pharma’s experimental obesity drug petr...

Impressions : 1177

AbbVie enters obesity race with US$ 2.23 bn deal with Denmark’s Gubra; Roche’s TNKase approved for treating strokes

AbbVie has forayed into the obesity treatment market with a US$ 2.23 billion licensing deal with Denmark’s Gubra for its ...

Impressions : 899

Lilly to invest US$ 27 bn in US as Trump threatens big pharma with tariffs; FDA scrambles to rehire after mass layoffs

In the US, President Donald Trump has been putting pressure on Big Pharma to reshore or face tariffs. Eli Lilly has been the ...

Impressions : 1006

US health agencies brace for more layoffs under RFK Jr; Novo alleges fraud in US$ 1.3 bn deal with KBP BioSciences

In this week’s Phispers, we bring you news from the public health agencies in the US that have already witnessed consider...

Impressions : 909

Bain buys Mitsubishi Tanabe for US$ 3.4 bn, Novartis acquires Anthos for US$ 3.1 bn, FDA okays AbbVie-Pfizer’s new antibiotic

In this week’s news, Bain Capital acquired Japanese pharma Mitsubishi Tanabe for US$ 3.4 billion. And Novartis acquired B...

Impressions : 1639

FDA okays Vertex’s non-opioid painkiller, Supernus’ wearable device for Parkinson’s; Sanofi, GSK plan share buybacks

While the healthcare sector in the US was embroiled in political uncertainties over tariffs and key appointments, the country&r...

Impressions : 656

FDA approves Ozempic to treat CKD in diabetes patients; AbbVie, Neomorph ink US$ 1.64 bn deal for molecular glue degraders

Novo Nordisk’s Ozempic became the first glucagon-like peptide 1 (GLP-1) drug to receive the US Food and Drug Administrati...

Impressions : 875

Trump withdraws US from WHO; Novo’s Ozempic, Wegovy among 15 new drugs chosen for price negotiations under IRA

On the day Donald Trump was sworn in as the 47th President of the United States, there was a deluge of some 200 measures, which...

Impressions : 1538

J&J buys Intra-Cellular for US$ 14.6 bn; FTC exposes PBMs’ US$ 7.3 bn drug price markup scheme

The week saw the J.P. Morgan Healthcare Conference kick off with a flurry of deals. In all, deals worth over US$ 19.3 billion ...

Impressions : 847

Novo bets up to US$ 4.6 bn on AI drug development, expands deal with Valo Health; WuXi sells Irish vaccine plant to Merck

As the embattled WuXi Biologics faces increasing pressure from the impending US Biosecure Act, it has decided to sell its vacci...

Impressions : 997

Lilly’s Zepbound becomes first FDA-approved therapy for sleep apnea; Novo wins nod for daily hemophilia shot

This week’s Phispers is a double bill with news from the last two weeks. Through much of December, the US Food and Drug A...

Impressions : 1126

Novo invests US$ 1.2 bn in new rare disease plant in Denmark; FDA approves two drugs for atopic dermatitis

As the year draws to a close, the US Food and Drug Administration (FDA) has been approving drugs at a feverish pace. It approve...

Impressions : 847

Lilly, Amgen inject billions into manufacturing; GSK’s Blenrep bests world’s top-selling myeloma drug

In Phispers this week, Eli Lilly announced an investment of US$ 3 billion towards building a new plant in Wisconsin (US) to me...

Impressions : 10910

Novartis snaps up PTC’s Huntington’s disease program in US$ 2.9 bn deal; Sanofi to set up insulin facility in China

In Phispers this week, we bring you news of how political changes in the US could impact the pharma industry. Big Pharma has r...

Impressions : 938

Sarepta inks US$ 11 bn RNA deal with Arrowhead; Roche expands CAR-T arsenal; Novartis buys Kate for US$ 1 bn

The week saw three large deals signed in promising fields. First, Sarepta Therapeutics signed a US$ 11.4 billion deal with Ar...

Impressions : 1677

Merck inks US$ 3.3 bn cancer deal with LaNova; vaccine makers’ stocks tumble after Trump picks RFK Jr to head HHS

This week, Merck struck a strategic US$ 3.3 billion deal with LaNova Medicines for a promising cancer drug, and also demonstr...

Impressions : 1148

Astra invests US$ 2 bn in US R&D; key AbbVie asset from US$ 8.7 bn Cerevel buy flunks phase 2 trials

This week’s Phispers is packed with news about deals. First, AstraZeneca announced a US$ 2 billion investment in the...

Impressions : 804

Astra faces probe in China; AbbVie, EvolveImmune ink potential US$ 1.4 bn deal; EC levies US$ 503 mn fine on Teva

In this week’s Phispers, AstraZeneca faces a major crisis in China as its president Leon Wang is under investigation in w...

Impressions : 964

AbbVie strengthens Alzheimer’s pipeline with US$ 1.4 bn Aliada buyout; Roche expands gene therapy pact with Dyno

This week’s Phispers is packed with latest developments in the field of Alzheimer’s disease, owing to a conference ...

Impressions : 851

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass